Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Free Cash Flow: 2020-2024

Historic Free Cash Flow for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$159.2 million.

  • NewAmsterdam Pharma Co N.V's Free Cash Flow fell 160.88% to -$32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.5 million, marking a year-over-year increase of 6.65%. This contributed to the annual value of -$159.2 million for FY2024, which is 12.74% down from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Free Cash Flow stood at -$159.2 million for FY2024, which was down 12.74% from -$141.2 million recorded in FY2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Free Cash Flow peaked at $10.4 million during FY2022, and registered a low of -$159.2 million during FY2024.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Free Cash Flow averaged around -$96.7 million, with its median value being -$141.2 million (2023).
  • As far as peak fluctuations go, NewAmsterdam Pharma Co N.V's Free Cash Flow skyrocketed by 135.36% in 2022, and later tumbled by 1,452.37% in 2023.
  • Yearly analysis of 5 years shows NewAmsterdam Pharma Co N.V's Free Cash Flow stood at -$6.8 million in 2020, then crashed by 332.37% to -$29.5 million in 2021, then spiked by 135.36% to $10.4 million in 2022, then plummeted by 1,452.37% to -$141.2 million in 2023, then fell by 12.74% to -$159.2 million in 2024.